Thr292
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr292  -  RAD9A (human)

Site Information
PQLQAHStPHPDDFA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2999204

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 2 ) , mutation of modification site ( 1 , 2 ) , phospho-antibody ( 1 , 2 ) , western blotting ( 1 , 2 )
Disease tissue studied:
ataxia-telangiectasia ( 2 )
Relevant cell line - cell type - tissue:
fibroblast ( 1 , 2 ) , HeLa (cervical) ( 1 , 2 ) , IMR-90 (fibroblast) ( 1 , 2 )

Upstream Regulation
Putative in vivo kinases:
CDK1 (human) ( 2 )
Treatments:
hydroxyurea ( 2 ) , ICRF-193 ( 1 ) , ionizing_radiation ( 2 ) , nocodazole ( 1 , 2 ) , seliciclib ( 2 )

References 

1

Greer Card DA, Sierant ML, Davey S (2010) Rad9A is required for G2 decatenation checkpoint and to prevent endoreduplication in response to topoisomerase II inhibition. J Biol Chem 285, 15653-61
20305300   Curated Info

2

St Onge RP, Besley BD, Pelley JL, Davey S (2003) A role for the phosphorylation of hRad9 in checkpoint signaling. J Biol Chem 278, 26620-8
12734188   Curated Info